Clinical Trial

Exercise Neuroprotection in Parkinson's Disease

Study acronym: PDex
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated September 3, 2024 (before its estimated May 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this study is to explore the relationships of exercise on inflammation in the body of older adults and people with Parkinson's disease (PD). This is important research for older adults but is especially important for people with PD because neuroinflammation is the main pathological mechanism that is responsible for neuron cell death in this neurodegenerative disease. As PD is a progressive disease, halting or slowing the degeneration is an important research target. Halting or slowing the disease progress is known as neuroprotection. Exercise is an attractive therapeutic treatment for people with PD as it has a lot of multi-systemic benefits, but also there is a lot of evidence to suggest that it helps improve symptoms and slow the progression of the disease. Exercise has been theorized to decrease inflammation and, therefore, has a lot of promise as a neuroprotective agent in slowing or halting the degeneration in PD. Unfortunately, there is not a lot of research that has looked into the effect of exercise on the biological processes of inflammation. Thus, the purpose of this study is to investigate the biological evidence that underlies the positive effect of exercise in people with PD.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-05-02; most recent amendment 2024-08-29.
Status change: Not Yet Recruiting → Recruiting 2024-08-29
Trial Details
NCT Number NCT05854524
Lead Sponsor University of Nevada, Las Vegas
Conditions Parkinson Disease
Enrollment 90 participants
Start Date 2024-08-29
Primary Completion 2026-05-30 (estimated)
Study Completion 2026-12-30 (estimated)
Updated on ClinicalTrials.gov 2024-09-03